Impact of the 2017 Blood Pressure Guidelines by the American Academy of Pediatrics in overweight/obese youth.


Journal

Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882

Informations de publication

Date de publication:
04 2019
Historique:
entrez: 1 3 2019
pubmed: 1 3 2019
medline: 10 6 2020
Statut: ppublish

Résumé

The aim of this study was to compare the impact of the European Society of Hypertension Guidelines 2016 (ESHG2016) and the American Academy of Pediatrics Guidelines 2017 (AAPG2017) on the screening of hypertension and classification of abnormal left ventricular geometry (ALVG) in overweight/obese youth. This study included 6137 overweight/obese youth; 437 had echocardiographic assessment. Hypertension was defined using either ESHG2016 or AAPG2017. ALVG was defined using 95th percentile for age and sex of left ventricular mass index (LVMi) and/or relative wall thickness (RWT) more than 0.38 (juvenile cut-offs) according to ESHG2016 or LVMi more than 51 g/h and/or RWT more than 0.42 (adult cut-offs) according to AAPG2017. Prevalence of youth at a high risk of hypertension was 13% higher using AAPG2017 than ESHG2016. The increase was larger in overweight youth at least 13 years of age (+43%). Using the juvenile cut-offs for ALVG, youth at a high risk of hypertension by ESHG2016 had an odds ratio [95% confidence interval (95% CI)] of 3.03 (1.31-7.05) for left ventricular concentric remodelling (LVcr) and 2.53 (1.43-4.47) for concentric left ventricular hypertrophy (cLVH) as compared with youth with normal LVG. Similarly, in youth at a high risk of hypertension by AAPG2017, the odds ratio for LVcr was 3.28 (1.45-7.41, P < 0.001) and 3.02 (95% CI: 1.73-5.27, P < 0.001) for cLVH. Using the adult cut-offs, no significant difference in ALVG was found with both guidelines. The prevalence of overweight/obese youth at a high risk of hypertension increased by 13% comparing AAPG2017 vs. ESHG2016. The juvenile cut-offs for ALVG were more effective than the adult criteria in intercepting individuals with a potentially higher cardiovascular risk.

Identifiants

pubmed: 30817454
doi: 10.1097/HJH.0000000000001954
pii: 00004872-201904000-00012
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

732-738

Auteurs

Procolo Di Bonito (P)

Department of Internal Medicine, 'S. Maria delle Grazie', Pozzuoli Hospital.

Giuliana Valerio (G)

Department of Movement Sciences and Wellbeing, University of Naples Parthenope, Naples.

Lucia Pacifico (L)

Policlinico Umberto I Hospital, Sapienza University of Rome.

Claudio Chiesa (C)

Institute of Translational Pharmacology, National Research Council, Rome.

Cecilia Invitti (C)

IRCCS Istituto Auxologico Italiano, Department of Medical Sciences & Rehabilitation, Milan.

Anita Morandi (A)

Pediatric Diabetes and Metabolic Disorders Unit, University Hospital of Verona, Verona.

Maria Rosaria Licenziati (MR)

Department of Pediatrics, AORN Santobono-Pausilipon, Naples.

Melania Manco (M)

IRCCS Bambino Gesù Children's Hospital, Rome.

Emanuele Miraglia Del Giudice (EMD)

Department of Woman, Child and General and Specialized Surgery, University of Campania 'Luigi Vanvitelli', Naples.

Marco Giorgio Baroni (MG)

Department of Experimental Medicine, Sapienza University of Rome, Rome.

Sandro Loche (S)

Pediatric Endocrine Unit, Pediatric hospital for microcitemia, AO Brotzu, Cagliari.

Gianluca Tornese (G)

Institute for maternal and child health IRCCS 'Burlo Garofolo', Trieste.

Francesca Franco (F)

Pediatric Unit, AOU Udine, Udine.

Claudio Maffeis (C)

Pediatric Diabetes and Metabolic Disorders Unit, University of Verona, Verona.

Giovanni de Simone (G)

Hypertension Research Center & Department of Translational Medical Sciences, Federico II University Naples, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH